autoimmune disease

Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant's report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced pain and inflammation and improved physical function in patients with moderately to severely active RA.

As kids we're told "don't go barefoot, you'll get worms!" But for millions suffering from allergies, mutiple sclerosis, Crohn's disease or other autoimmune diseases without relief, an innovative treatment might be in order: A hookworm infection.